Notice! For experimental use only. Autologous Prescription Product, Code 95A7.50 (unlicensed) is a service provided by Torigen Pharmaceuticals, Inc. and is regulated by the USDA Center for Veterinary Biologics. Treatment is administered only to the stated animal. Efficacy and safety have not been established by the USDA.
Torigen educational seminar opportunity
About Torigen's autologous prescription product
Affordable and accessible cancer treatment options for your practice
Over 4 million dogs and 4 million cats are diagnosed with cancer each year. 50% of all dogs over the age of 10 die from cancer, yet limited options exist to pet parents aside from chemotherapy and radiation therapy.
Torigen is a team of veterinarians and cancer researchers who have come together to help pets with cancer.
Torigen’s autologous prescription product is a individualized cancer vaccine made from the patient’s own tumor cells.
We aim to train the immune system to fight cancer
- After a tumor is surgically excised, it is sent into our laboratory where we prepare a individualized treatment utilizing the patient’s own tumor cells.
- Our approach is called an Autologous Whole Cell Tissue vaccine that drives lymphocyte recognition of tumor antigens and stromal.
- We offer a simple and accessible treatment option that can be completed with both oncologists and with general practice.
This form of cancer immunotherapy may be appropriate for any solid tumor, including:
- Sarcoma
- Carcinoma
- Melanoma
- Sarcoid
- etc.
Straightforward administration in any clinical setting. No personal protective equipment required.
Interested in learning more?
Download this brochure and read our peer-reviewed literature.
Learn more about Torigen.